Is Insulet Stock Underperforming the Dow?

Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Valued at a market cap of $16 billion, the company is best known for its Omnipod platform, a tubeless insulin delivery system. Beyond its core diabetes care focus, it leverages its proprietary Pod technology for the subcutaneous delivery of non-insulin drugs across various therapeutic areas.

Companies worth $10 billion or more are typically classified as “large-cap stocks,” and PODD fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the medical devices industry. The company operates a high-volume manufacturing and pharmacy-channel distribution model, serving over 600,000 customers across approximately 25 countries.